Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$10.26-3.3%$11.47$5.90▼$14.51$684.53M1.79746,204 shs1.14 million shsLGNDLigand Pharmaceuticals$232.55+0.1%$211.74$98.89▼$247.38$4.65B1.2220,161 shs185,392 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas+0.95%+3.82%-2.21%-20.76%+39.06%LGNDLigand Pharmaceuticals+2.14%-0.01%+16.39%+17.13%+118.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$10.26-3.3%$11.47$5.90▼$14.51$684.53M1.79746,204 shs1.14 million shsLGNDLigand Pharmaceuticals$232.55+0.1%$211.74$98.89▼$247.38$4.65B1.2220,161 shs185,392 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas+0.95%+3.82%-2.21%-20.76%+39.06%LGNDLigand Pharmaceuticals+2.14%-0.01%+16.39%+17.13%+118.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.38Hold$14.6042.30% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$256.2910.21% UpsideCurrent Analyst Ratings BreakdownLatest ARVN and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026ARVNArvinas CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $24.005/1/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/30/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$243.00 ➝ $289.004/28/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$235.00 ➝ $252.004/27/2026ARVNArvinas Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/15/2026LGNDLigand Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$276.00 ➝ $282.004/14/2026LGNDLigand Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$239.00 ➝ $243.004/10/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026LGNDLigand Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $276.003/19/2026ARVNArvinas CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $21.003/19/2026ARVNArvinas BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $16.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$262.60M2.52N/AN/A$6.76 per share1.52LGNDLigand Pharmaceuticals$268.09M17.38$7.86 per share29.58$51.68 per share4.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$80.80M-$1.28N/AN/AN/A-30.77%-14.25%-9.31%5/7/2026 (Estimated)LGNDLigand Pharmaceuticals$124.45M$5.8339.8931.511.6846.42%13.86%10.18%5/6/2026 (Estimated)Latest ARVN and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LGNDLigand Pharmaceuticals$1.84N/AN/AN/A$59.10 millionN/A5/7/2026Q1 2026ARVNArvinas-$0.94N/AN/AN/A$16.61 millionN/A2/26/2026Q4 2025LGNDLigand Pharmaceuticals$1.46$2.02+$0.56$2.12$55.59 million$59.67 million2/24/2026Q4 2025ARVNArvinas-$0.55-$1.10-$0.55-$1.10$37.26 million$9.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.924.92LGNDLigand Pharmaceuticals0.4422.2321.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42064.52 million61.47 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableARVN and LGND HeadlinesRecent News About These CompaniesOrchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced ...May 6 at 1:20 PM | caledonianrecord.comCLigand to Participate in May Investor ConferencesMay 5 at 4:01 PM | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 SharesMay 5 at 4:19 AM | insidertrades.comInsider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells 5,000 Shares of StockMay 4 at 8:47 PM | marketbeat.comBank of America Securities Keeps Their Buy Rating on Ligand Pharma (LGND)May 2, 2026 | theglobeandmail.comLigand Pharmaceuticals Incorporated $LGND Shares Sold by Kornitzer Capital Management Inc. KSMay 2, 2026 | marketbeat.comHC Wainwright Brokers Increase Earnings Estimates for LGNDMay 1, 2026 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 1, 2026 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Given New $289.00 Price Target at HC WainwrightMay 1, 2026 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 1, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock PriceApril 30, 2026 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down - Here's WhyApril 29, 2026 | marketbeat.comMoody Aldrich Partners LLC Has $3.70 Million Stock Holdings in Ligand Pharmaceuticals Incorporated $LGNDApril 29, 2026 | marketbeat.comRoyal Bank Of Canada Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock PriceApril 28, 2026 | marketbeat.comLigand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS OutlookApril 27, 2026 | marketbeat.comLigand Pharmaceuticals Incorporated (LGND) XOMA Royalty Corporation - M&A Call - SlideshowApril 27, 2026 | seekingalpha.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty CorporationApril 27, 2026 | prnewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High - Still a Buy?April 27, 2026 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings GuidanceApril 27, 2026 | marketbeat.comLigand Pharmaceuticals Incorporated (LGND) M&A Call TranscriptApril 27, 2026 | seekingalpha.comLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN and LGND Company DescriptionsArvinas NASDAQ:ARVN$10.26 -0.35 (-3.30%) Closing price 04:00 PM EasternExtended Trading$10.47 +0.21 (+2.05%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Ligand Pharmaceuticals NASDAQ:LGND$232.55 +0.25 (+0.11%) Closing price 04:00 PM EasternExtended Trading$232.17 -0.38 (-0.16%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
